Clinical Trial

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

WATERTOWN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to…

1 year ago

Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology

SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted…

1 year ago

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader

KT-621 has demonstrated dupilumab-like activity and was well tolerated ina wide variety of preclinical models of TH2 diseases KT-621 is…

1 year ago

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Poster presentations include new preclinical data demonstrating activity for palazestrant in combination with capivasertib and everolimus, and OP-3136, Olema’s KAT6…

1 year ago

FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer

RAMAT GAN, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company…

1 year ago

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial

MALVERN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused…

1 year ago

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

- Maintained Stable Visual Acuity and Anatomical Control Over 9 Months - - Positive Safety Profile with No Ocular or…

1 year ago

XORTX Initiates Precision Medicine Program

Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine MetabolismCALGARY, Alberta, Oct.…

1 year ago

BioCorteX Unveils Critical Bacteria Interactions in ADC Cancer Treatment, Enabled by Google Cloud

LONDON, Oct. 9, 2024 /PRNewswire/ -- BioCorteX, a leading biotech innovator, today formally announced a breakthrough in the field of Antibody-Drug…

1 year ago

AWAK Transforms into Vivance, Unveiling a New Brand Identity

SINGAPORE, Oct. 9, 2024 /PRNewswire/ -- AWAK Technologies, a pioneer in innovative kidney care is excited to announce its rebranding…

1 year ago